Overview

  • Product nameAnti-Met (c-Met) antibody [8F11]See all Met (c-Met) primary antibodies ...
  • Description
    Mouse monoclonal [8F11] to Met (c-Met)
  • Tested applicationsIHC-Fr, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Prokaryotic recombinant protein corresponding to the external domain of the beta chain of the cMET molecule.

  • Positive control
    • Human Prostate epithelium.

Properties

Applications

Our Abpromise guarantee covers the use of ab49210 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr 1/20 - 1/30.
IHC-P 1/20 - 1/30. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. Incubate with primary antibody for 60 minutes at 25°C using standard ABC method.
  • Application notesIs unsuitable for WB.
  • Target

    • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • DomainThe kinase domain is involved in SPSB1 binding.
    • Post-translational
      modifications
      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • AUTS9 antibody
      • c met antibody
      • cmet antibody
      • D249 antibody
      • Hepatocyte growth factor receptor antibody
      • Hepatocyte growth factor receptor Precursor antibody
      • HGF antibody
      • HGF receptor antibody
      • HGF SF receptor antibody
      • HGF/SF receptor antibody
      • HGFR antibody
      • MET antibody
      • Met proto oncogene tyrosine kinase antibody
      • Met proto-oncogene (hepatocyte growth factor receptor) antibody
      • Met proto-oncogene antibody
      • Met protooncogene antibody
      • MET_HUMAN antibody
      • Oncogene MET antibody
      • Par4 antibody
      • Proto-oncogene c-Met antibody
      • RCCP2 antibody
      • Renal cell carcinoma papillary 2 gene antibody
      • Scatter factor receptor antibody
      • SF receptor antibody
      • Tyrosine-protein kinase Met antibody
      see all

    References for Anti-Met (c-Met) antibody [8F11] (ab49210)

    This product has been referenced in:
    • Basak SK  et al. The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression. PLoS One 8:e73195 (2013). Read more (PubMed: 24019906) »
    • Stein U  et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59-67 (2009). IHC-P ; Human . Read more (PubMed: 19098908) »

    See all 3 Publications for this product

    Product Wall

    With regard to the antibody NCL-cmet, a full assessment of the antibody was published in Claire Chapman's thesis (Newcastle University). This can be accessed via Pub Med Central the thesis title is:- Role of c-met in response to liver injury and i...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"